TABLE 1.
Risk effect of the detection of enterovirus RNA in serum for later development of clinical type 1 diabetes
| Time period | OR | 95% CI | P |
|---|---|---|---|
| Boys and girls | |||
| Birth-before Aab | 6.2 | 1.8–21 | <0.004 |
| Birth-before 6 month period prior Aab | 3.1 | 0.4–22.4 | <0.27 |
| 6 month period prior Aab | 7.7 | 1.9–31.5 | <0.004 |
| Boys | |||
| Birth-before Aab | 18.8 | 2.2–163.7 | <0.008 |
| Birth-before 6 month period prior Aab | 3.9 | 0.2–63.3 | <0.34 |
| 6 month period prior Aab | 18.2 | 2.0–164.5 | <0.01 |
| Girls | |||
| Birth-before Aab | 2.6 | 0.5–12.3 | <0.24 |
| Birth-before 6 month period prior Aab | 2.4 | 0.2–39.7 | <0.53 |
| 6 month period prior Aab | 3.1 | 0.4–21.8 | <0.26 |
6 month period prior AAb, 6-month time window before autoantibody seroconversion; birth-before 6 month period prior Aab, time from birth to 6 months before the seroconversion to positivity for the first autoantibody; birth-before Aab, time from birth to the seroconversion to positivity for the first autoantibody.